StreetAlpha.app
Home › Stocks › OLMA

Olema Oncology, Inc. (OLMA)

Healthcare
$7.02
▼ −1.82%
LAST CLOSE · NOV 20

Olema Pharmaceuticals develops experimental oral drugs for breast cancer, based in San Francisco. It last closed at $7.02 on Nov 20, down 1.82% on the day. The next earnings report for OLMA is expected around Mon, Jan 11, 2027, after the close. For the quarter ended Sep 2026, OLMA reported EPS of -$0.73. Over its last 8 reports the stock moved an average of 7.5% the session after earnings. Over the last 12 months OLMA insiders bought $0 of stock on the open market and sold $24.7M, according to SEC Form 4 filings.

AI Auto Pilots
Is OLMA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold OLMA.

Key Stats

Last 12 months
Results
Net income
−$235.9M
EPS (diluted)
−$2.40
Valuation
Market cap
$615.0M
87.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$47.5M
At Sep 30
Shareholder equity
$368.8M
Shares outstanding
87.6M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$71.1M−$71.1MFY2021FY2022: −$104.8M−$104.8MFY2022FY2023: −$96.7M−$96.7MFY2023FY2024: −$129.5M−$129.5MFY2024FY2025: −$162.5M−$162.5MFY2025

From OLMA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · After the close
Reported EPS
-$0.73
Quarter ended Sep 2026
Year ago EPS
-$0.49
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.40Dec '24Mar 2025: -$0.36Mar '25Jun 2025: -$0.51Jun '25Sep 2025: -$0.49Sep '25Dec 2025: -$0.51Dec '25Mar 2026: -$0.52Mar '26Jun 2026: -$0.61Jun '26Sep 2026: -$0.73Sep '26Latest -$0.73
Revenue by quarter
Not enough quarters on file yet.
How OLMA moved after its last 8 reports
Average move the session after a report ±7.5%
Nov 10, 2026Time not announced−1.2%
Aug 10, 2026After the close−12.7%
May 12, 2026Time not announced−6.0%
Mar 16, 2026Time not announced+12.8%
Jan 12, 2026After the close−3.1%
Nov 10, 2025Time not announced+4.2%
Aug 11, 2025After the close+16.2%
May 13, 2025After the close−3.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on OLMAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on OLMA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on OLMA

Technical Analysis

OLMA · as of the Nov 20 close · updated each morning
Downtrend

The stock is 3% below its 20 day and 12% below its 50 day average. It is 80% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 44). The nearest support is the Pivot S1 at $6.81, and the nearest resistance the Pivot at $7.08.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 8.0%/day
Key levels
$36.2652 week high+416.5%
$12.62200 day average+79.8%
$9.56100 day average+36.2%
$7.8450 day average+11.7%
$7.60Swing high (Oct 29)+8.3%
$7.29Pivot R1+3.8%
$7.2520 day average+3.3%
$7.08Pivot+0.9%
$7.02Last close
$6.81Pivot S1−3.0%
$6.71Swing low (Nov 5)−4.4%
$6.2452 week low−11.1%
Indicators
RSI (14)43.84Middle of its rangeNeutral
MACD-0.15Above its signal lineBullish
Stochastic23.7Middle of its rangeNeutral
ADX (14)19.6No clear trend
Williams %R-79.9Oversold below −80, overbought above −20Neutral
CCI (20)-49.3Oversold below −100, overbought above 100Neutral
Rate of change−4.2%Change over 10 sessionsBearish
ATR (14)$0.56Typical daily range, 8.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for OLMA

What happened before

See how OLMA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow OLMA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How OLMA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for OLMAHow many large options trades hit OLMA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

OLMA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲98 buying vs 75 selling
  • ●Held by funds +0.3 pts
  • ▼Funds holding -5
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding180185−2.7%
In funds' top 10220.0%
Held by funds116.6%116.3%+0.3 pts
New / increased26 / 7223 / 74+1.0%
Reduced / sold out44 / 3160 / 35−21.1%
Put/call ratio0.020.11−85.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OLMA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

OLMA Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$24.7M10 sales · 6 insiders
2025-12 sold $17.0M2026-01 sold $6.5M2026-03 sold $952K2026-07 sold $291KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jul 24Cyrus HarmonDirectorSale25,000$11.65$291K
Mar 4Shawnte MitchellChief Legal OfficerSale40,000$23.79$952K
Jan 20Cyrus HarmonDirectorSale10,000$26.88$269K
Jan 15Shane William Charles KovacsCh. Operating & Financial Off.Sale103,822$28.70$3.0M
Jan 14Cyrus HarmonDirectorSale3,489$29.12$102K
Jan 14David C. MylesCh. Discov. & Non-clin Dev OffSale110,000$28.25$3.1M
Every insider buy and sale for OLMA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See OLMA insider trades →

From SEC Form 4 filings by OLMA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OLMA is in one of them and how their past OLMA trades turned out.

OLMA in the AI portfolios
Loading…

OLMA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OLMA in an article yet. Here's the latest on the wider market.

OLMA in the news

About Olema Oncology

Olema Pharmaceuticals is a drug developer based in San Francisco, California. It is developing oral medicines for breast cancer, led by palazestrant, an experimental drug that blocks the estrogen receptor and breaks it down. The company is also developing OP3136, a treatment that targets the KAT6 protein. If approved, these drugs would be prescribed to women with breast cancer. None of its products are approved for sale yet, so it has no product sales.

Headquarters
South San Francisco, CA